The risk of microscopic colitis in solid-organ transplantation patients: A population-based study

Transplantation

Volumn 85, Issue 1, 2008, Pages 48-54

  Kaplan, Gilaad G ^a,b   Seminowich, Sansira ^a   Williams, Jennifer ^a,b   Muruve, Daniel ^a   Dupre, Marc ^a   Urbanski, Stefan J ^a   Yilmaz, Serdar ^a   Burak, Kelly W ^a,b   Beck, Paul L ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Collagenous colitis; Lymphocytic colitis; Microscopic colitis; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BISMUTH SALICYLATE; BUDESONIDE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPERAMIDE; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC COLITIS; MORBIDITY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; CHRONIC DISEASE; COHORT STUDIES; COLITIS; DIARRHEA; FEMALE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUCOUS MEMBRANE; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; RISK FACTORS;

EID: 38149128259     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000298001.66377.a2     Document Type: Article

References (67)

1. Abdo AA, Urbanski SJ, Beck PL. Lymphocytic and collagenous colitis: The emerging entity of microscopic colitis. An update on pathophysiology, diagnosis and management. Can J Gastroenterol 2003; 17: 425.
2. Lindstrom CG. 'Collagenous colitis' with watery diarrhoea - a new entity? Pathol Eur 1976; 11: 87.
3. Freeman HJ, Weinstein WM, Shnitka TK, Wensel RH, Sartor VE. Watery diarrhea syndrome associated with a lesion of the colonic basement membrane-lamina propria interface. Ann R Coll Phys Surg Can. 1976; 9: 45.
4. Read NW, Krejs GJ, Read MG, Santa Ana CA, Morawski SG, Fordtran JS. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78: 264.
5. Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C. Lymphocytic colitis: A retrospective clinical study of 199 Swedish patients. Gut 2004; 53: 536.
6. Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C. Microscopic colitis: A common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 2004; 53: 346.
7. Williams J, Kaplan GG, Makhija S, Urbanski S, Panaccione R, Beck PL. Population-based study of the epidemiology of and the risk factors for microscopic colitis. Can J Gastroenterol. 2005; 19(Suppl B): 8.
8. Erdem L, Yildirim S, Yilmaz B, Orhan S, Gultekin H, Koksal M, et al. The rate of microscopic colitis in patients with chronic diarrhea with unknown etiology. Gastroenterology 2002; 122: W1608.
9. Pardi DS, Loftus EV, Jr., Smyrk TC, Kammer P, Tremaine WJ, Schleck CD, et al. The epidemiology of microscopic colitis: A population-based study in Olmsted County, Minnesota. Gut 2007; 56: 1033.
10. Fine KD, Do K, Schulte K, Ogunji F, Guerra R, Osowski L, et al. High prevalence of celiac sprue-like HLA-DQ genes and enteropathy in patients with the microscopic colitis syndrome. Am J Gastroenterol 2000; 95: 1974.
11. Kandemir O, Utas C, Gonen O, Patiroglu TE, Ozbakir O, Kelestimur F, et al. Colonic subepithelial collagenous thickening in diabetic patients. Dis Colon Rectum 1995; 38: 1097.
12. Tysk C, Bohr J, Olesen M, Eriksson S, Jarnerot G. [Microscopic colitis-more common cause of diarrhea than believed. Biopsies are the only way to diagnosis, drug treatment is effective.] Lakartidningen. 2005; 102: 2210.
13. Cindoruk M, Tuncer C, Dursun A, Yetkin I, Karakan T, Cakir N, et al. Increased colonic intraepithelial lymphocytes in patients with Hashimoto's thyroiditis. J Clin Gastroenterol 2002; 34: 237.
14. van Tilburg AJ, Lam HG, Seldenrijk CA, Stel HV, Blok P, Dekker W, et al. Familial occurrence of collagenous colitis. A report of two families. J Clin Gastroenterol 1990; 12: 279.
15. Giardiello FM, Bayless TM, Jessurun J, Hamilton SR, Yardley JH. Collagenous colitis: Physiologic and histopathologic studies in seven patients. Ann Intern Med 1987; 106: 46.
16. Giardiello FM, Hansen FC, 3rd, Lazenby AJ, Hellman DB, Milligan FD, Bayless TM, et al. Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257.
17. Fernandez-Banares F, Esteve M, Espinos JC, Rosinach M, Forne M, Salas A, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007; 102: 324.
18. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: A case-control study. Gut 1992; 33: 683.
19. Chande N, McDonald JW, MacDonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2006: CD003575.
20. Dumortier J, Gagnieu MC, Salandre J, Guillaud O, Guillem P, Adham M, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study. Liver Transpl 2006; 12: 1342.
21. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: Etiology and management. Liver Transpl 2005; 11: 881.
22. Maes B, Hadaya K, de Moor B, Cambier P, Peeters P, de Meester J, et al. Severe diarrhea in renal transplant patients: Results of the DIDACT study. Am J Transplant 2006; 6: 1466.
23. Worns MA, Lohse AW, Neurath MF, Croxford A, Otto G, Kreft A, et al. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1931.
24. Verdonk RC, Dijkstra G, Haagsma EB, Shostrom VK, Van den Berg AP, Kleibeuker JH, et al. Inflammatory bowel disease after liver transplantation: Risk factors for recurrence and de novo disease. Am J Transplant 6: 1422, 2006.
25. Calgary Health Region. Hospital and Community Health Care Sites. Available at: http://www.calgaryhealthregion.ca/hospitals/index.html. Accessed November 7, 2007.
26. Statistics Canada. 2001 Community Profiles. Available at: http://www12.statcan.ca/english/Profil01/CP01/Index.cfm?Lang=E. Accessed November 7, 2007.
27. Warren BF, Edwards CM, Travis SP. 'Microscopic colitis': Classification and terminology. Histopathology 2002; 40: 374.
28. Bohr J, Tysk C, Eriksson S, Abrahamsson H, Jarnerot G. Collagenous colitis: A retrospective study of clinical presentation and treatment in 163 patients. Gut 1996; 39: 846.
29. Hochleitner BW, Bosmuller C, Nehoda H, Fruhwirt M, Simma B, Ellemunter H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001; 14: 230.
30. Berengue JI, Lopez-Espinosa JA, Ortega-Lopez J, Sanchez-Sanchez L, Castilla-Valdes P, Asensio-Llorente M, et al. Two- to three-fold increase in blood tacrolimus (FK506) levels during diarrhea in livertransplanted children. Clin Transplant 2003; 17: 249.
31. Pierrugues R, Bories P, Barneon G, Bernard N, Michel H. [Collagen colitis. Reflections apropos of 40 patients.] Gastroenterol Clin Biol. 1989; 13: 811.
32. Baert F, Wouters K, D'Haens G, Hoang P, Naegels S, D'Heygere F, et al. Lymphocytic colitis: A distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut 1999; 45: 375.
33. Jarnerot G, Hertervig E, Granno C, Thorhallsson E, Eriksson S, Tysk C, et al. Familial occurrence of microscopic colitis: A report on five families. Scand J Gastroenterol 2001; 36: 959.
34. Hilmer SN, Heap TR, Eckstein RP, Lauer CS, Shenfield GM. Microscopic colitis associated with exposure to lansoprazole. Med J Aust 2006; 184: 185.
35. Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, et al. Histologic features of mycophenolate mofetil-related colitis: A graft-versus-host disease-like pattern. Intl J Surg Pathol 2003; 11: 295.
36. Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665.
37. Watanabe M, Yuzawa K, Homma M, Ohkohchi N. Establishment of an animal model with side effects induced by mycophenolate mofetil and pharmacohistological analysis of them. Transplant Proc 2006; 38: 3323.
38. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001; 24: 645.
39. Koulaouzidis A, Henry JA, Saeed AA. Mucosal tears can occur spontaneously in collagenous colitis. Endoscopy 2006; 38: 549.
40. Klein A. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. Liver Transpl Surg 1999; 5: 502.
41. Nagarajan S, Friedrich T, Garcia M, Kambham N, Sarwal MM. Gastro-intestinal leukocytoclastic vasculitis: An adverse effect of sirolimus. Pediatr Transplant 2005; 9: 97.
42. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28: 153.
43. Lapointe M, Baillie GM, Bhaskar SS, Richardson MS, Self SE, Baliga PK, et al. Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. Clin Transplant 1999; 13: 526.
44. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Systematic Rev (Online). 2005(4): CD003961.
45. Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: A 3-yr sequential study. Clin Transplant 2002; 16: 163.
46. Oh JM, Wiland AM, Klassen DK, Weidle PJ, Bartlett ST. Comparison of azathioprine and mycophenolate mofetil for the prevention of acute rejection in recipients of pancreas transplantation. J Clin Pharmacol 2001; 41: 861.
47. Nyhlin N, Bohr J, Eriksson S, Tysk C. Systematic review: Microscopic colitis. Aliment Pharmacol Ther 2006; 23: 1525.
48. Mielke S, Heymer P, Bethke B, Bastlein E, Meier E, Bartram H, et al. Budesonide treatment for colagenous colitis: A randomized doubleblind, placebo-controlled, multicenter trial. Gastroenterology 2002; 123: 978.
49. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601.
50. Tromm A, Griga T, Mollmann HW, May B, Muller KM, Fisseler-Eckhoff A. Budesonide for the treatment of collagenous colitis: First results of a pilot trial. Am J Gastroenterol 1999; 94: 1871.
51. Madisch A, Heymer P, Voss C, Wigginghaus B, Bastlein E, Bayerdorffer E, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis 2005; 20: 312.
52. Chopra A, Pardi DS, Loftus EV, Jr., Tremaine WJ, Egan LJ, Faubion WA, et al. Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice. Inflamm Bowel Dis 2006; 12: 29.
53. Abdo AA, Beck P. Diagnosis and management of microscopic colitis. Can Fam Physician 2003; 49: 1473.
54. Wang N, Dumot JA, Achkar E, Easley KA, Petras RE, Goldblum JR. Colonic epithelial lymphocytosis without a thickened subepithelial collagen table: A clinicopathologic study of 40 cases supporting a heterogeneous entity. Am J Surg Pathol 1999; 23: 1068.
55. Freeman HJ. Functional asplenia and microscopic (collagenous) colitis. Can J Gastroenterol 1996; 10: 443.
56. Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279.
57. Ramji A, Owen DA, Erb SR, Scudamore CH, Yoshida EM. Post-liver transplant Crohn's disease: Graft tolerance but not self-tolerance? Dig Dis Sci 2002; 47: 522.
58. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, Aguilera I, Perera-Molinero A, Moneva-Arce E, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc 2006; 38: 1467.
59. Mosnier JF, Larvol L, Barge J, Dubois S, De La Bigne G, Henin D, et al. Lymphocytic and collagenous colitis: An immunohistochemical study. Am J Gastroenterol 1996; 91: 709.
60. Tagkalidis PP, Gibson P, Bhathal PS. Microscopic colitis demonstrates a TH1 mucosal cytokine profile. J Clin Pathol 2007; 60: 382.
61. Hibbs AM, Bznik-Cizman B, Guttenberg M, Goldberg B, Meyers K. Ulcerative colitis in a renal transplant patient with previous Goodpasture disease. Pediatr Nephrol 2001; 16: 543.
62. Hultkrantz S, Ostman S, Telemo E. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology 2005; 116: 362.
63. Turnbull EL, Yrlid U, Jenkins CD, Macpherson GG. Intestinal dendritic cell subsets: Differential effects of systemic TLR4 stimulation on migratory fate and activation in vivo. J Immunol 2005; 174: 1374.
64. Shlomai A, Trop S, Gotsman I, Jurim O, Diment J, Alper R, et al. Immunomodulation of experimental colitis: The role of NK1.1 liver lymphocytes and surrogate antigens - bystander effect. J Pathol 2001; 195: 498.
65. Yang R, Liu Q, Grosfeld JL, Pescovitz MD. Intestinal venous drainage through the liver is a prerequisite for oral tolerance induction. J Pediatr Surg 1994; 29: 1145.
66. Jaskiewicz K, Rzepko R, Adrych K, Smoczynski M. Microscopic colitis in routine colonoscopies. Dig Dis Sci 2006; 51: 241.
67. Cross A, Treanor D, Keegan D, Sheahan K, Mulcathy H, O'Donoghue D. Microscopic colitis-Increased incidence or increased recognition? Gastroenterology. 2002; 122: A-602.